Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 1-2/2015

01.01.2015 | main topic

Efficacy and safety of rituximab in rheumatic diseases

verfasst von: MD Eva Rath, Jochen Zwerina, Bastian Oppl, Valerie Nell-Duxneuner

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 1-2/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

B-cell depleting therapy is now in clinical use for more than 10 years in rheumatology. In 2001, a first report was published on five rheumatoid arthritis patients responding to the chimeric anti-CD20 antibody rituximab. Since then, numerous clinical trials, prospective and retrospective studies, registry data as well as case reports on the use of rituximab in autoimmune rheumatic diseases have been published. This review gives a short overview on clinical data of rituximab in rheumatic diseases currently available.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(9):2793–806. CrossRefPubMed Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54(9):2793–806. CrossRefPubMed
2.
Zurück zum Zitat Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70(1):39–46. CrossRefPubMed Tak PP, Rigby WF, Rubbert-Roth A, et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70(1):39–46. CrossRefPubMed
3.
Zurück zum Zitat Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69(9):1629–35. CrossRefPubMedCentralPubMed Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab’s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69(9):1629–35. CrossRefPubMedCentralPubMed
4.
Zurück zum Zitat Emery P, Fleischmann RM, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390–400. CrossRefPubMed Emery P, Fleischmann RM, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390–400. CrossRefPubMed
5.
Zurück zum Zitat Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49(9):1683–93. CrossRef Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49(9):1683–93. CrossRef
6.
Zurück zum Zitat Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68(1):25–32. CrossRefPubMedCentralPubMed Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68(1):25–32. CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625–32. CrossRefPubMed Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625–32. CrossRefPubMed
8.
Zurück zum Zitat Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70(9):1575–80. CrossRefPubMed Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70(9):1575–80. CrossRefPubMed
9.
Zurück zum Zitat Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71(3):374–7. CrossRefPubMed Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71(3):374–7. CrossRefPubMed
10.
Zurück zum Zitat Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2012;64(8):1108–15. Soliman MM, Hyrich KL, Lunt M, et al. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken). 2012;64(8):1108–15.
11.
Zurück zum Zitat Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69(2):387–93. CrossRefPubMedCentralPubMed Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis. 2010;69(2):387–93. CrossRefPubMedCentralPubMed
12.
Zurück zum Zitat Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-203993 Emery P, Gottenberg JE, Rubbert-Roth A, et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-203993
13.
14.
Zurück zum Zitat Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20. CrossRefPubMed Jones RB, Tervaert JWC, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211–20. CrossRefPubMed
15.
Zurück zum Zitat Jones RB, Walsh M, Jayne DR, et al. Two year follow-up results from a randomised trial of RTX versus Cyp for ANCA-associated vasculitis: RITUXVAS. Clin Exp Immunol. 2011;164(Suppl 1):57. CrossRef Jones RB, Walsh M, Jayne DR, et al. Two year follow-up results from a randomised trial of RTX versus Cyp for ANCA-associated vasculitis: RITUXVAS. Clin Exp Immunol. 2011;164(Suppl 1):57. CrossRef
16.
Zurück zum Zitat Roll P, Ostermeier E, Haubitz M, et al. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol. 2012;39(11):2153–6. CrossRefPubMed Roll P, Ostermeier E, Haubitz M, et al. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol. 2012;39(11):2153–6. CrossRefPubMed
17.
Zurück zum Zitat Taylor SRJ, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum. 2009;60(5):1540–7. CrossRefPubMed Taylor SRJ, Salama AD, Joshi L, et al. Rituximab is effective in the treatment of refractory ophthalmic Wegener’s granulomatosis. Arthritis Rheum. 2009;60(5):1540–7. CrossRefPubMed
18.
Zurück zum Zitat Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis. 2006;65(7):853–8. CrossRefPubMedCentralPubMed Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener’s granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis. 2006;65(7):853–8. CrossRefPubMedCentralPubMed
19.
Zurück zum Zitat Bawa S, Mukhtyar C, Edmonds S, et al. Refractory Wegener’s meningitis treated with rituximab. J Rheumatol. 2007;34(4):900–1. PubMed Bawa S, Mukhtyar C, Edmonds S, et al. Refractory Wegener’s meningitis treated with rituximab. J Rheumatol. 2007;34(4):900–1. PubMed
20.
Zurück zum Zitat Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. Arthritis Rheum. 2013;64(Suppl 10):706. Guillevin L, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. Arthritis Rheum. 2013;64(Suppl 10):706.
21.
Zurück zum Zitat Terrier B, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in anit neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (MAINRITSAN): follow-up at 34 months. Ann Rheum Dis. 2013;72(Suppl 3):124. CrossRef Terrier B, Pagnoux C, Karras A, et al. Rituximab versus azathioprine for maintenance in anit neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (MAINRITSAN): follow-up at 34 months. Ann Rheum Dis. 2013;72(Suppl 3):124. CrossRef
22.
Zurück zum Zitat Jones RB, Smith R, Guerry M-J, et al. Protocolised versus non-protocolised rituximab treatment for refractory ANCA-associated vasculitis. Arthritis Rheum. 2010;62(Suppl 10):678. Jones RB, Smith R, Guerry M-J, et al. Protocolised versus non-protocolised rituximab treatment for refractory ANCA-associated vasculitis. Arthritis Rheum. 2010;62(Suppl 10):678.
23.
Zurück zum Zitat Ng KP, Leandro MJ, Edwards JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis. 2006;65(7):942–5. CrossRefPubMedCentralPubMed Ng KP, Leandro MJ, Edwards JC, et al. Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis. 2006;65(7):942–5. CrossRefPubMedCentralPubMed
24.
Zurück zum Zitat Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long term follow up and predictors of response. Ann Rheum Dis. 2007;66(9):1259–62. CrossRefPubMedCentralPubMed Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long term follow up and predictors of response. Ann Rheum Dis. 2007;66(9):1259–62. CrossRefPubMedCentralPubMed
25.
Zurück zum Zitat Lu TYT, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college London hospital: the first 50 patients. Arthritis Rheum. 2009;61(4):482–7. CrossRefPubMed Lu TYT, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college London hospital: the first 50 patients. Arthritis Rheum. 2009;61(4):482–7. CrossRefPubMed
26.
Zurück zum Zitat Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituxamab registry. Arthritis Rheum. 2010;62(8):2458–66. CrossRefPubMed Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituxamab registry. Arthritis Rheum. 2010;62(8):2458–66. CrossRefPubMed
27.
Zurück zum Zitat Fernández-Nebro A, Marenco De la Fuente JL, Carreño L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2012;21(10):1063–76. CrossRefPubMed Fernández-Nebro A, Marenco De la Fuente JL, Carreño L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: the LESIMAB study. Lupus. 2012;21(10):1063–76. CrossRefPubMed
28.
Zurück zum Zitat Ramos-Casals M, García-Hernández FJ, de Ramón E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28(4):468–76. PubMed Ramos-Casals M, García-Hernández FJ, de Ramón E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. Clin Exp Rheumatol. 2010;28(4):468–76. PubMed
29.
Zurück zum Zitat Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33. CrossRefPubMed Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62(1):222–33. CrossRefPubMed
30.
Zurück zum Zitat Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–26. CrossRefPubMed Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–26. CrossRefPubMed
31.
Zurück zum Zitat Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960–8. CrossRefPubMed Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62(4):960–8. CrossRefPubMed
32.
Zurück zum Zitat Devauchelle-Pensec V, Mariette X, Jousse-Jolin S, et al. Treatment of primary Sjögren’s syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233–42. CrossRefPubMed Devauchelle-Pensec V, Mariette X, Jousse-Jolin S, et al. Treatment of primary Sjögren’s syndrome with rituximab: a randomized trial. Ann Intern Med. 2014;160(4):233–42. CrossRefPubMed
33.
Zurück zum Zitat Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541–4. CrossRefPubMed Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67(11):1541–4. CrossRefPubMed
34.
Zurück zum Zitat St Clair EW, Levesque MC, Luning Prak ET, et al. Rituximab therapy for primary Sjogren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65(4):1097–106. CrossRef St Clair EW, Levesque MC, Luning Prak ET, et al. Rituximab therapy for primary Sjogren’s syndrome: an open-label clinical trial and mechanistic analysis. Arthritis Rheum. 2013;65(4):1097–106. CrossRef
35.
Zurück zum Zitat Gottenberg J-E, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026–31. CrossRefPubMed Gottenberg J-E, Cinquetti G, Larroche C, et al. Efficacy of rituximab in systemic manifestations of primary Sjögren’s syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026–31. CrossRefPubMed
36.
Zurück zum Zitat Mekinian A, Ravaud P, Larroche C, et al. Rituximab in central nervous system manifestations of patients with primary Sjögren’s syndrome: results from the AIR registry. Clin Exp Rheumatol. 2012;30(2):208–12. PubMed Mekinian A, Ravaud P, Larroche C, et al. Rituximab in central nervous system manifestations of patients with primary Sjögren’s syndrome: results from the AIR registry. Clin Exp Rheumatol. 2012;30(2):208–12. PubMed
37.
Zurück zum Zitat Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71(1):84–7. CrossRefPubMed Mekinian A, Ravaud P, Hatron PY, et al. Efficacy of rituximab in primary Sjögren’s syndrome with peripheral nervous system involvement: results from the AIR registry. Ann Rheum Dis. 2012;71(1):84–7. CrossRefPubMed
38.
Zurück zum Zitat Yamout B, El-Hajj T, Barada W, et al. Successful treatment of refractory neuroSjogren with rituximab. Lupus. 2007;16(7):521–3. CrossRefPubMed Yamout B, El-Hajj T, Barada W, et al. Successful treatment of refractory neuroSjogren with rituximab. Lupus. 2007;16(7):521–3. CrossRefPubMed
39.
Zurück zum Zitat Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren’s syndrome with rituximab. Scand J Rheumatol. 2006;35(4):323–5. CrossRefPubMed Touma Z, Sayad J, Arayssi T. Successful treatment of Sjogren’s syndrome with rituximab. Scand J Rheumatol. 2006;35(4):323–5. CrossRefPubMed
40.
Zurück zum Zitat Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24. CrossRefPubMedCentralPubMed Oddis CV, Reed AM, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24. CrossRefPubMedCentralPubMed
41.
Zurück zum Zitat Munoz-Beamud F, Isenberg DA. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2013;31(6):896–903. PubMed Munoz-Beamud F, Isenberg DA. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2013;31(6):896–903. PubMed
42.
Zurück zum Zitat Mahler EAM, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford). 2011;50(12):2206–13. CrossRef Mahler EAM, Blom M, Voermans NC, et al. Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology (Oxford). 2011;50(12):2206–13. CrossRef
43.
Zurück zum Zitat Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52(2):601–7. CrossRefPubMed Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52(2):601–7. CrossRefPubMed
44.
Zurück zum Zitat Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome-a retrospective case series. Rheumatology (Oxford). 2009;48(8):968–71. CrossRef Sem M, Molberg O, Lund MB, et al. Rituximab treatment of the anti-synthetase syndrome-a retrospective case series. Rheumatology (Oxford). 2009;48(8):968–71. CrossRef
45.
Zurück zum Zitat Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord. 2006;16(5):334–6. CrossRefPubMed Arlet JB, Dimitri D, Pagnoux C, et al. Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP). Neuromuscul Disord. 2006;16(5):334–6. CrossRefPubMed
46.
Zurück zum Zitat Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012;40(3):641–48. CrossRefPubMed Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J. 2012;40(3):641–48. CrossRefPubMed
47.
Zurück zum Zitat Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006;33(5):1021–6. PubMed Noss EH, Hausner-Sypek DL, Weinblatt ME. Rituximab as therapy for refractory polymyositis and dermatomyositis. J Rheumatol. 2006;33(5):1021–6. PubMed
48.
Zurück zum Zitat Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford). 2009;48(5):594–5. CrossRef Whelan BR, Isenberg DA. Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion. Rheumatology (Oxford). 2009;48(5):594–5. CrossRef
49.
Zurück zum Zitat Frikha F, Rigolet A, Behin A, et al. Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases. Rheumatology (Oxford). 2009;48(9):1166–8. CrossRef Frikha F, Rigolet A, Behin A, et al. Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases. Rheumatology (Oxford). 2009;48(9):1166–8. CrossRef
50.
Zurück zum Zitat Unger L, Kampf S, Lüthke K, et al. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford). 2014 Sep;53(9):1630–8 Unger L, Kampf S, Lüthke K, et al. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford). 2014 Sep;53(9):1630–8
51.
Zurück zum Zitat Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12(2):R54. CrossRefPubMedCentralPubMed Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther. 2010;12(2):R54. CrossRefPubMedCentralPubMed
52.
Zurück zum Zitat Daoussis D, Antonopoulos I, Liossis S-NC, et al. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum. 2012;41(6):822–9. CrossRefPubMed Daoussis D, Antonopoulos I, Liossis S-NC, et al. Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature. Semin Arthritis Rheum. 2012;41(6):822–9. CrossRefPubMed
53.
Zurück zum Zitat Daoussis D, Liossis S-NC, Tsamandas AC, et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum. 2010;40(2):127–36. CrossRefPubMed Daoussis D, Liossis S-NC, Tsamandas AC, et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum. 2010;40(2):127–36. CrossRefPubMed
54.
Zurück zum Zitat Daoussis D, Liossis S-NC, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271–80. CrossRef Daoussis D, Liossis S-NC, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology (Oxford). 2010;49(2):271–80. CrossRef
55.
Zurück zum Zitat Fabri M, Hunzelmann N, Krieg T, et al. Discordant response to rituximab in a systemic sclerosis patient with associated myositis. J Am Acad Dermatol. 2008;58(5 Suppl 1):S127–8. CrossRefPubMed Fabri M, Hunzelmann N, Krieg T, et al. Discordant response to rituximab in a systemic sclerosis patient with associated myositis. J Am Acad Dermatol. 2008;58(5 Suppl 1):S127–8. CrossRefPubMed
56.
Zurück zum Zitat Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578–83. CrossRefPubMedCentralPubMed Lafyatis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum. 2009;60(2):578–83. CrossRefPubMedCentralPubMed
57.
Zurück zum Zitat McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford). 2008;47(4):552–3. CrossRef McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology (Oxford). 2008;47(4):552–3. CrossRef
58.
Zurück zum Zitat Smith V, Piette Y, Van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52–7. CrossRefPubMed Smith V, Piette Y, Van Praet JT, et al. Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol. 2013;40(1):52–7. CrossRefPubMed
59.
Zurück zum Zitat Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193–7. CrossRefPubMed Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study. Ann Rheum Dis. 2010;69(1):193–7. CrossRefPubMed
60.
Zurück zum Zitat Traverse W, Tremazi J, Lakshminarayanan S. Rituximab use in a case of alveolitis and myositis in the context of systemic scleroderma. Arthritis Rheum. 2005;52(12):4104–5. Traverse W, Tremazi J, Lakshminarayanan S. Rituximab use in a case of alveolitis and myositis in the context of systemic scleroderma. Arthritis Rheum. 2005;52(12):4104–5.
61.
Zurück zum Zitat Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma trial and Research (EUSTAR) group. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204522 Jordan S, Distler JH, Maurer B, et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma trial and Research (EUSTAR) group. Ann Rheum Dis. 2014. doi:10.1136/annrheumdis-2013-204522
62.
Zurück zum Zitat Hoyer B F, Mumtaz I M, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheumatic Dis. 2012;71(1):75–9. CrossRef Hoyer B F, Mumtaz I M, Loddenkemper K, et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheumatic Dis. 2012;71(1):75–9. CrossRef
63.
Zurück zum Zitat Schaefer VS, Zwerina J. Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol. 2012;24(1):31–7. CrossRef Schaefer VS, Zwerina J. Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol. 2012;24(1):31–7. CrossRef
64.
Zurück zum Zitat Ernst D, Greer M, Stoll M, et al. Remission achieved in refractory advanced Takayasu arteritis using rituximab. Case Rep Rheumatol. 2012;2012:406963. PubMedCentralPubMed Ernst D, Greer M, Stoll M, et al. Remission achieved in refractory advanced Takayasu arteritis using rituximab. Case Rep Rheumatol. 2012;2012:406963. PubMedCentralPubMed
66.
Zurück zum Zitat Mitroulis I, Hatzara C, Kandili A, et al. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2013;72(2):308–10. CrossRefPubMed Mitroulis I, Hatzara C, Kandili A, et al. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis. 2013;72(2):308–10. CrossRefPubMed
67.
Zurück zum Zitat Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in system lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60(12):3761–5. CrossRefPubMed Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy: a national estimate of frequency in system lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 2009;60(12):3761–5. CrossRefPubMed
68.
Zurück zum Zitat Bharat A, Xie F, Baddley JW, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken). 2012;64(4):612–5. CrossRef Bharat A, Xie F, Baddley JW, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken). 2012;64(4):612–5. CrossRef
69.
Zurück zum Zitat Amend KL, Turnbull B, Foskett N, et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology. 2010;75(15):1326–32. CrossRefPubMed Amend KL, Turnbull B, Foskett N, et al. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology. 2010;75(15):1326–32. CrossRefPubMed
70.
Zurück zum Zitat Arkema EV, Van Vollenhoven RF, Askling J. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. Ann Rheum Dis. 2012;71(11):1865–7. CrossRefPubMed Arkema EV, Van Vollenhoven RF, Askling J. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. Ann Rheum Dis. 2012;71(11):1865–7. CrossRefPubMed
71.
Zurück zum Zitat Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev. 2008;8(2):144–6. CrossRefPubMed Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk? Autoimmun Rev. 2008;8(2):144–6. CrossRefPubMed
72.
Zurück zum Zitat Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043–51. CrossRefPubMed Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043–51. CrossRefPubMed
73.
Zurück zum Zitat Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225–8. CrossRefPubMed Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225–8. CrossRefPubMed
74.
Zurück zum Zitat Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156–64. CrossRefPubMedCentralPubMed Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156–64. CrossRefPubMedCentralPubMed
75.
Zurück zum Zitat Abdulkader R, Dharamapalaiah C, Rose G, et al. Late-onset Neutropenia in patients with Rheumatoid Arthritis after treatment with rituximab. J Rheumatol. 2014;41(5):858–61. CrossRefPubMed Abdulkader R, Dharamapalaiah C, Rose G, et al. Late-onset Neutropenia in patients with Rheumatoid Arthritis after treatment with rituximab. J Rheumatol. 2014;41(5):858–61. CrossRefPubMed
76.
Zurück zum Zitat Tesfa D, Ajeganova S, Hägglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63(8):2209–14. CrossRefPubMed Tesfa D, Ajeganova S, Hägglund H, et al. Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections. Arthritis Rheum. 2011;63(8):2209–14. CrossRefPubMed
Metadaten
Titel
Efficacy and safety of rituximab in rheumatic diseases
verfasst von
MD Eva Rath
Jochen Zwerina
Bastian Oppl
Valerie Nell-Duxneuner
Publikationsdatum
01.01.2015
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 1-2/2015
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-014-0331-8